215303-72-3

中文名稱 4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑

英文名稱 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol

CAS 215303-72-3

分子式 C27H24FN3O

分子量 425.5

MOL 文件 215303-72-3.mol

更新日期 2024/12/13 09:53:00

215303-72-3 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑價(jià)格(試劑級(jí)) 常見問題列表

基本信息

中文別名

4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑

英文別名

CS-1470
RWJ 67657
JNJ 3026582
RWJ-67657
JNJ-3026582
RWJ-67657
RWJ-67657
RWJ-67657
4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-phenylpropyl)-5-(4-Pyridyl)iMidazole
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol
3-Butyn-1-ol, 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-
4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol ISO 9001：2015 REACH

所屬類別

醫(yī)藥中間體：羥基吡啶

物理化學(xué)性質(zhì)

熔點(diǎn)124℃

沸點(diǎn)611.8±65.0 °C(Predicted)

密度1.14±0.1 g/cm3(Predicted)

儲(chǔ)存條件Store at RT

溶解度≤10mg/ml in ethanol;5mg/ml in DMSO;2mg/ml in dimethyl formamide

酸度系數(shù)(pKa)14.37±0.10(Predicted)

形態(tài)黃色粉末

顏色Light yellow to yellow

InChI1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2

InChIKeyQSUSKMBNZQHHPA-UHFFFAOYSA-N

SMILESOCCC#CC1=NC(C2=CC=C(F)C=C2)=C(C3=CC=NC=C3)N1CCCC4=CC=CC=C4

安全數(shù)據(jù)

WGK GermanyWGK 3

存儲(chǔ)類別11 - Combustible Solids

圖譜信息

4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑(215303-72-3)核磁圖(¹HNMR)

4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-15505R	4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 (Standard)	215303-72-3	5 mg	1750元
2026/06/05	HY-15505R	4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 (Standard)	215303-72-3	10 mg	2800元
2026/06/05	HY-15505R	4-(4-氟苯基)-2-(4-羥基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 RWJ-67657 (Standard)	215303-72-3	25 mg	5600元

常見問題列表

生物活性

RWJ-67657 (JNJ 3026582) 是一種具有口服活性的選擇性 p38α 和 p38β 抑制劑，IC50 分別為 1 和 11 μM。RWJ-67657 對(duì) p38γ 和 p38δ 無活性，是心臟保護(hù)劑，具有抗炎和抗腫瘤活性。

靶點(diǎn)

p38α

1 μM (IC ₅₀ )

p38β

11 μM (IC ₅₀ )

體外研究

RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC ₅₀ of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC ₅₀ value of 13 nM.
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells.

Cell Proliferation Assay

Cell Line:	MCF-7 breast carcinoma cells
Concentration:	10 μM
Incubation Time:	24 hours
Result:	Decreased colony formation.

體內(nèi)研究

RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration.
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke.

Animal Model:	The db/db mice (male, 8 weeks old) with EPCs
Dosage:	50 mg/kg
Administration:	Administered orally; once per day for 7 consecutive days
Result:	Increased angiogenesis and neurogenesis of diabetic mice after cotreatment with EPCs transplantation.